Hip cartilage cannot grow back — this is why

The short answer is no — damaged hip cartilage does not grow back on its own, and this is not a matter of waiting long enough.

Adult articular cartilage, the smooth tissue lining the ball and socket of the hip joint, has no blood supply. Nutrients reach it only by slow diffusion from synovial fluid and from the bone immediately beneath. Because no blood flows to a damaged area, none of the circulating stem cells that repair other tissues can reach it. Once the growth plates close after puberty, this limitation becomes permanent: the joint has no mechanism to replenish lost cartilage, however minor the original injury.

The clinical consequence of leaving a focal defect untreated — commonly one produced by femoroacetabular impingement (FAI) — is progressive enlargement. Each loading cycle concentrates stress at the exposed edges of the lesion. Over months and years, neighbouring cartilage breaks down under that abnormal pressure. What begins as a contained, focal Grade III or IV chondral lesion can advance to diffuse, bone-on-bone arthritis if nothing interrupts that cycle.

This is not a gloomy framing for its own sake; it is the biological reality that makes structural intervention worth weighing. If the tissue cannot repair itself, the question becomes whether something introduced into the hip joint can do what the body no longer can.

What rest, supplements, and routine injections actually achieve

Conservative management deserves genuine credit before its limits are explained. Rest, physiotherapy, and weight reduction all reduce mechanical load on the hip joint, and for many patients that translates into meaningful pain relief, better function, and a slower rate of surface wear. These are not trivial outcomes.

Oral glucosamine and chondroitin occupy a similar position: some patients report modest symptom improvement, and evidence supports a role in managing discomfort for certain individuals. No peer-reviewed data, however, support structural cartilage regeneration from supplementation alone.

Hyaluronic acid (viscosupplementation) injections add lubrication to the hip joint, and retrospective cohort evidence suggests they can improve short-term comfort in symptomatic osteoarthritis. What they cannot do is provide a structural scaffold at the defect site or recruit progenitor cells to begin remodelling. The joint moves more easily; nothing fills or repairs the lesion itself.

Corticosteroid injections are effective anti-inflammatories — short-term pain reduction is real — but they carry no restorative function, and clinical experience suggests repeated use may impair the quality of remaining tissue over time.

All of these options sit firmly at the symptom-management stage of the hip care pathway. Genuine structural repair at the defect site is a different order of task entirely: it requires something physically present within the lesion — a scaffold the body's own progenitor cells can migrate into, populate, and remodel.

What ChondroFiller injection does inside the hip joint

The procedure begins with image-guided needle placement. Under ultrasound guidance and local anaesthesia — no general anaesthetic, no operating theatre — the ChondroFiller solution is deposited precisely into the focal cartilage defect within the hip joint. ChondroFiller is a purified, acellular Type I collagen supplied in a ready-to-use two-chamber syringe, manufactured in Germany by Meidrix Biomedicals GmbH, and holds CE-marked Class III medical device status.

Once inside the joint, the collagen polymerises at body temperature. Within approximately three to five minutes it sets into a dimensionally stable, three-dimensional hydrogel that conforms to the individual shape and depth of the lesion — without fibrin glue, bone drilling, or microfracturing.

That scaffold then begins its biological work through a process called matrix-induced chondrogenesis: the scaffold signals the body's own repair cells to migrate in. Because ChondroFiller is acellular, no prior biopsy or laboratory cell-culturing step is required. This is a meaningful distinction from autologous chondrocyte implantation (ACI) and MACI, both of which involve harvesting cartilage, expanding cells over weeks in culture, and returning for a separate implantation procedure. ChondroFiller instead draws the patient's own mesenchymal progenitor cells from the surrounding synovium and subchondral bone, providing both the physical framework and the biochemical environment they need to settle and differentiate.

Over three to six months, those recruited cells progressively remodel the collagen matrix into fibrocartilage-like repair tissue. This repair tissue is fibrocartilage-like rather than true hyaline cartilage, and the original collagen resorbs naturally as remodelling matures — leaving tissue generated by the patient's own biology rather than a permanent foreign implant. A 2021 study by Perez-Carro et al. (PMC8322278) confirmed this approach as viable for full-thickness acetabular defects in the hip, with promising early results, while noting that long-term data continue to accumulate.

Which hip patients are suitable for ChondroFiller injection

Candidacy for ChondroFiller injection rests on defect characteristics more than age alone. The ideal patient has a focal, full-thickness cartilage lesion graded III or IV on the ICRS/Outerbridge scale — meaning damage reaching deep into or through the cartilage layer — with healthy tissue bordering the defect on all sides. This profile most commonly arises from femoroacetabular impingement (FAI), where a structural mismatch between the femoral head and acetabulum concentrates shear forces that progressively strip cartilage from the acetabular rim.

Lesion size matters. Clinical evidence supports ChondroFiller injection for defects up to approximately 3 cm², with some protocols extending to 6 cm² where defect geometry allows adequate scaffold fill.

Age is not a fixed gate. A 55-year-old with a contained focal defect and well-preserved surrounding cartilage may be better placed than a younger patient with diffuse early degeneration across the whole joint surface. What counts is whether a discrete, bordered lesion exists for the scaffold to occupy and the surrounding tissue to support.

Advanced diffuse osteoarthritis — Kellgren-Lawrence Grade IV, bone-on-bone loss across the joint — falls outside the indication. Without intact surrounding cartilage to anchor and stabilise the scaffold, joint replacement or salvage surgery becomes the more appropriate discussion.

Patients who have previously undergone microfracture may still be assessed, but bone plate changes from drilling can affect scaffold integration; thorough pre-procedure imaging is essential in those cases.

A brief distinction is worth noting here: where ChondroFiller injection targets the defect itself as a regenerative scaffold, Arthrosamid is a non-degradable polyacrylamide hydrogel that cushions the joint lining — a different mechanism serving a different clinical role. Some patients suit one and not the other. Suitability is confirmed through clinical examination and MRI rather than symptom description alone.

What the clinical evidence shows — and where uncertainty remains

Peer-reviewed evidence for ChondroFiller injection in the hip points to a genuine clinical signal — and an honest account of what the data currently do and do not establish matters as much as the numbers themselves.

The strongest hip-specific anchor is a 2021 study by Perez-Carro et al. (PMC8322278), which confirmed injectable ChondroFiller as a viable one-step procedure for full-thickness acetabular cartilage defects, with promising early results. Hip-specific outcome data show approximately 30-point modified Harris Hip Score (mHHS) gains at 12 months in suitable candidates — a clinically meaningful improvement in both pain and function.

Pooled across hip, knee, and smaller joints, published data report that 70–85% of patients achieve significant symptom relief, with a complaint rate of approximately 0.06%. MRI evidence adds structural confirmation: MOCART scores of 70–87 indicate good defect fill rather than symptom masking alone. These pooled figures span multiple joints — that should be stated plainly — and hip-specific long-term randomised controlled trial data are still accumulating. The early evidence is promising; it is not yet complete.

As covered in the mechanism section, the repair tissue produced is fibrocartilage-like rather than original hyaline cartilage. Its durability under the sustained load demands of the hip joint is one of the questions current research continues to address.

For patients considering this pathway, a practical consideration connects directly to this evidence picture: ChondroFiller injection is not NHS-funded and is offered as self-funded private treatment in the UK, which places it in a different category from routine intra-articular injections when patients are weighing their options.

Recovery timeline and accessing ChondroFiller injection in Lincolnshire

ChondroFiller injection is delivered as an outpatient procedure under ultrasound or fluoroscopic guidance — no general anaesthetic, no hospital stay.

Recovery follows three broad phases. For approximately the first six weeks, partial weight-bearing protects the newly placed scaffold as it stabilises against the joint surface and begins drawing in the patient's own progenitor cells. Between months two and six, those recruited cells progressively remodel the collagen matrix into fibrocartilage-like repair tissue. From month six onward, load-bearing activity increases gradually, with a return to high-impact exercise targeting twelve months as the repair tissue continues to mature. Individual timelines vary with defect size, severity, and overall joint condition.

The thread running through this article comes to a practical point here. Adult hip cartilage lacks the blood supply to recruit repair cells on its own — that biological constraint is unchanged by any intervention. What ChondroFiller injection provides is the structural and biochemical environment that cartilage biology cannot create unaided: a scaffold that does the recruitment work the tissue itself cannot do. For patients with a suitable focal defect, understanding that distinction — regenerative support rather than guaranteed tissue replacement — is the basis on which a realistic treatment decision rests.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients for hip assessment without a GP referral, with clinics at Sleaford and Grantham. An initial consultation includes clinical examination and imaging to confirm defect grade, lesion size, and surrounding cartilage health before any treatment is recommended.